

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/853,161
				Filing Date	May 11, 2001
				First Named Inventor	RUBEN, et al.
				Group Art Unit	1634
				Examiner Name	Sheinberg, M.
Sheet	1	of	2	Attorney Docket Number	PZ003P3

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RKH	A	5,536,637		Kenneth Jacobs	07/16/1996	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				
RKH	B	EP	0679 716A		Matsubara et al.	11/02/1995	
	C	WO	97/07198		Genetics Inst. Inc.	02/27/1997	
	D	WO	00/09709		Incyte	02/24/2000	
RKH	E	WO	98/40483		Human Genome Sciences	09/17/1998	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
RKH	F	Geneseq Accession No: Y12863, DUCLERT et al., "Human 5' EST secreted protein SEQ ID NO:453" (June 21, 1999).		
	G	GenBank Accession No: R60718, HILLIER et al., "yh02c10.r1 Homo sapiens cDNA clone 42116 5'" (May 29, 1995).		
	H	GenBank Accession No: T30875, ADAMS et al., "EST24351 Homo sapiens cDNA 5' end similar to None" (Jan. 11, 1995).		
	I	GenBank Accession No: N30539, HILLIER et al., "yx49g02.r1 Homo sapiens cDNA clone 265106 5'" (Jan. 6, 1996).		
	J	GenBank Accession No: H28536, HILLIER et al., "y159b11.r1 Homo sapiens cDNA clone 162525 5'" (July 19, 1995).		
	K	GenBank Accession No: H22240, HILLIER et al., "y131h11.s1 Homo sapiens cDNA clone 159909 3'" (July 8, 1995).		
RKH	L	GenBank Accession No: H56776, DIATCHENKO et al., "EST0040 Testis, Subtracted Homo sapiens cDNA clone LUDA-ST6, mRNA sequence" (Oct. 4, 1995).		

Examiner Signature	<i>Raoul K. Hammitt</i>	Date Considered	10/7/04
--------------------	-------------------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/853,161-Conf. #5950
				Filing Date	May 11, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1647
				Examiner Name	R. B. Kapust
Sheet	1	of	1	Attorney Docket Number	PZ003P3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
RKM	AB	WO-01/36979-A2	05-25-2001	University of Reading		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RKM	AC	KOTANI, H. et al., "Structure and gene organization of bovine neuromedin K precursor," Proc. Natl. Acad. Sci., USA, 83:7074-7078, (1986).	
	AD	KANGAWA, K. et al., "Neuromedin K: A Novel Mammalian Tachykinin Identified In Porcine Spinal Cord," Biochemical and Biophysical Research Communications, 114(2):533-540, ((1983).	
	AE	NAGASHIMA, A. et al., "Cardiovascular roles of tachykinin peptides in the nucleus tractus solitarii of rats," Brain Reearch, 487:392-396, (1989).	
	AF	ROCCON, A. et al., "Study of SR 14281, a new potent non-peptide NK <sub>3</sub> receptor antagonist on cardiovascular responses in conscious guinea-pig," British Journal of Pharmacology, 118:1095-1102, (1996).	
	AG	BROWNBILL, P. et al., "Neurokinin B Is a Paracrine Vasodilator in the Human Fetal Placental Circulation," Journal of Clinical Endocrinology and Metabolism, 88(5):2164-2170, (2003).	
	AH	PAGE, N.M. et al., "Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia," Nature, 405:797-800, (2000).	
RKM	AI	Swiss-Prot entry Q9UHFO, "TKNK HUMAN," (2001).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Rachel K. Hymowitz	Date Considered	10/7/04
-----------------------	--------------------	--------------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	09/853,161-Conf. #5950
				Filing Date	May 11, 2001
				First Named Inventor	Steven M. Ruben
				Art Unit	1647
				Examiner Name	R. B. Kapust
Sheet	1	of	1	Attorney Docket Number	PZ003P3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	AB	WO-01/36979-A2		05-25-2001	University of Reading		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	KOTANI, H. et al., "Structure and gene organization of bovine neuromedin K precursor," Proc. Natl. Acad. Sci., USA, 83:7074-7078, (1986).	
	AD	KANGAWA, K. et al., "Neuromedin K: A Novel Mammalian Tachykinin Identified In Porcine Spinal Cord," Biochemical and Biophysical Research Communications, 114(2):533-540, ((1983).	
	AE	NAGASHIMA, A. et al., "Cardiovascular roles of tachykinin peptides in the nucleus tractus solitarii of rats," Brain Research, 487:392-396, (1989).	
	AF	ROCCON, A. et al., "Study of SR 14281, a new potent non-peptide NK <sub>3</sub> receptor antagonist on cardiovascular responses in conscious guinea-pig," British Journal of Pharmacology, 118:1095-1102, (1996).	
	AG	BROWNBILL, P. et al., "Neurokinin B Is a Paracrine Vasodilator in the Human Fetal Placental Circulation," Journal of Clinical Endocrinology and Metabolism, 88(5):2164-2170, (2003).	
	AH	PAGE, N.M. et al., "Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia," Nature, 405:797-800, (2000).	
	AI	Swiss-Prot entry Q9UHFO, "TKNK HUMAN," (2001).	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

# RETURN RECEIPT CARD

(MPEP § 503)

<b>OIPE:</b>	Please Date Stamp In The Box Below And Return To Addressee
	

Application of:  
Ruben et al.

Docket No.: PZ003P3

Application Serial No.: 09/853,161-Conf. #5950

Art Unit: 1647

Filed: May 11, 2001

Examiner: R. B. Kapust

Title: Antibodies to Protein HPMBQ91 (As Amended)

The following documents were filed by Human Genome Sciences, Inc.  
via hand delivery on March 19, 2004:

1. Return Receipt Postcard;
2. Fee Transmittal charging \$290 to deposit account (in duplicate);
3. Response Under 37 C.F.R. § 1.111;
4. Exhibits A and B;
5. Declaration Under 37 C.F.R. § 1.132 by Dr. Viktor Roschke with attached Exhibits 1-6;
6. Second Supplemental Information Disclosure Statement (2 pages);
7. Form PTO/SB/08 with copies of references AB-AI; and
8. A One Month Extension of Time.

Sender's Initials: JMM/KM/vsr

Docket No.: PZ003P3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Ruben et al.

Application No.: 09/853,161

Confirmation No.:

Filed: May 11, 2001

Art Unit: 1647

For: Antibodies to Protein HPMBQ91 (As  
Amended)

---

Examiner: R. B. Kapust

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT PURSUANT TO 37 § CFR 1.56**


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AB-AI listed on the attached Form PTO/SB/08. A copy of each of references AB-AI is enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.



Applicants respectfully request that the Examiner review the listed references and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(2), the Patent Office will consider this Second Supplemental Information Disclosure Statement if filed before the mailing date of a final Office Action under §1.113, a Notice of Allowance under §1.311, or an action that otherwise closes prosecution in this application and accompanied by the fee set forth in § 1.17(p). Accordingly, the required fee of \$180.00 is transmitted herewith with the concurrently filed Fee Transmittal.

Please charge our Deposit Account No. 08-3425 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 08-3425.

Dated: March 19, 2004

Respectfully submitted,

By   
Janet M. Martineau

Registration No.: 46,903

HUMAN GENOME SCIENCES, INC.  
14200 Shady Grove Road  
Rockville, Maryland 20850  
(301) 315-2723